secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2023-10-23T23:59:59+00:00
Accession:  0001140361-23-049083
Event type: m_and_a
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst announces CSRC approval for business combination with Beijing Continent
--------------------------------------------------------------------------------

- Beijing Continent Pharmaceuticals received CSRC approval on Oct 20, 2023 for the business combination.
- Business Combination Agreement dated Dec 26, 2022, as amended, involves Catalyst and GNI entities.
- Parties anticipate completion by the outside date as defined in the agreement.
- Closing remains subject to satisfaction of other conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036123049083/0001140361-23-049083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036123049083/ef20012969_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-049083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer